Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CJRB 101

Next Previous
X
Search
Drug Profile

CJRB 101

Alternative Names: CJRB-101

Latest Information Update: 26 Dec 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CJ Bioscience
  • Class Antineoplastics; Bacteria; Immunotherapies
  • Mechanism of Action Microbiome modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Cancer

Most Recent Events

  • 11 Sep 2023 Phase-I/II clinical trials in Cancer (Combination therapy, Inoperable/Unresectable, Late-stage disease, Refractory Metastatic disease) in South Korea (PO) (NCT05877430)
  • 02 Jun 2023 CJ Bioscience plans a phase I/II trial in Cancer (Late-stage disease, Refractory metastatic disease, Combination therapy, Inoperable/Unresectable, Second-line or greater therapy, First-line therapy) in September 2023 (NCT05877430)
  • 02 Jun 2023 Preclinical trials in Cancer in South Korea (unspecified route) (CJ Bioscience website, June 2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top